1Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy
2Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy;Center for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy
3Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy
Journal of Food and Nutrition Research.
2019,
Vol. 7 No. 8, 554-559
DOI: 10.12691/jfnr-7-8-1
Copyright © 2019 Science and Education PublishingCite this paper: Giuseppe Derosa, Davide Romano, Angela D’Angelo, Pamela Maffioli. Effects of a Non Dairy Cheese Cream Containing Fermented Soybean Extract on Lipid Profile and Lipoproteins in Dyslipidemic Patients.
Journal of Food and Nutrition Research. 2019; 7(8):554-559. doi: 10.12691/jfnr-7-8-1.
Correspondence to: Giuseppe Derosa, Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy. Email:
giuseppe.derosa@unipv.itAbstract
Aim: to evaluate the effects of a non dairy cheese cream containing fermented soybean extract compared to a dairy cheese cream on lipid profile and lipoproteins in dyslipidemic patients. Methods: patients were randomized to take, twice a day on a slice of bread, a non dairy cheese cream, containing fermented soybean extract 75% (Valsoia Lo spalmabile®), or a placebo dairy cheese cream for 3 months, in a double-blind, placebo-controlled study design. We evaluated, at baseline and after 3 months: anthropometric parameters, fasting plasma glucose (FPG), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), lipoprotein (a) [Lp(a)], apolipoprotein A-I (Apo A-I), apolipoprotein B (Apo B), high-sensitivity C-reactive protein (Hs-CRP). Results: we did not record any variation of FPG. Total cholesterol, LDL-C and Tg decreased after 3 months with the active treatment, both compared to baseline and placebo (p < 0.05 for both). No variations were recorded with placebo. High density cholesterol did not change in neither group. We recorded a decrease of Apo-B and Hs-CRP with the active treatment, but not with placebo, compared to baseline (p < 0.05 for both), even if, in group to group comparison, only Apo-B resulted lower compared to placebo (p < 0.05). Lp(a) and Apo-A1 did not differ between treatments or compared to baseline. Conclusions: a non dairy cheese cream, containing fermented soybean extract 75%, better improved lipid profile compared to placebo dairy cheese cream in dyslipidemic patients.
Keywords